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Abstract
In this study, we examined the effect of chronic administration of simvastatin immediately after status epilepticus (SE) on rat
brain with temporal lobe epilepsy (TLE). First, we evaluated cytokines expression at 3 days post KA-lesion in hippocampus
and found that simvastatin-treatment suppressed lesion-induced expression of interleukin (IL)-1b and tumor necrosis factor-
a (TNF-a). Further, we quantified reactive astrocytosis using glial fibrillary acidic protein (GFAP) staining and neuron loss
using Nissl staining in hippocampus at 4–6 months after KA-lesion. We found that simvastatin suppressed reactive
astrocytosis demonstrated by a significant decrease in GFAP-positive cells, and attenuated loss of pyramidal neurons in CA3
and interneurons in dentate hilar (DH). We next assessed aberrant mossy fiber sprouting (MFS) that is known to contribute
to recurrence of spontaneous seizure in epileptic brain. In contrast to the robust MFS observed in saline-treated animals, the
extent of MFS was restrained by simvastatin in epileptic rats. Attenuated MFS was related to decreased neuronal loss in CA3
and DH, which is possibly a mechanism underlying decreased hippocampal susceptibility in animal treated with simvastatin.
Electronic encephalography (EEG) was recorded during 4 to 6 months after KA-lesion. The frequency of abnormal spikes in
rats with simvastatin-treatment decreased significantly compared to the saline group. In summary, simvastatin treatment
suppressed cytokines expression and reactive astrocytosis and decreased the frequency of discharges of epileptic brain,
which might be due to the inhibition of MFS in DH. Our study suggests that simvastatin administration might be a possible
intervention and promising strategy for preventing SE exacerbating to chronic epilepsy.
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Introduction
Epilepsy, characterized by recurrent spontaneous seizures,
affects 50 million people worldwide [1]. About 30% of epileptic
patients have temporal lobe epilepsy (TLE). TLE, which
eventually leads to cognitive deficits, can not be controlled by
antiepileptic drugs or surgical removal of epileptic focus [2], [3].
Therefore, there is a need to develop an alternative therapeutic
treatment to restrain exacerbation from acute status epilepticus
(SE) to chronic epilepsy. TLE is associated with neuropathological
changes, including hippocampal sclerosis and neurodegeneration,
and extensive reorganization of hippocampal circuits [4–8].
Interventions that reduces inflammation cascade and neuron
death have been shown to inhibit abnormal spikes and efficacious
for restraining TLE after initial precipitating injury (IPI) [9–13].
Statins are inhibitors of 3-hydroxy-3-methylglutaryl coenzyme
A (HMG-CoA) reductase and inhibit cellular synthesis of chole-
sterol and isoprenoids [14], [15]. Statins have been recognized for
their efficacy in reducing serum cholesterol level and prevention of
cardiovascular disease, while growing evidence has shown the
efficacy of statins in treating neurodegenerative diseases and
possibly traumatic brain injury [16]. The neuroprotective efficacy
of statins might be related to their properties such as endothelial
protection, antioxidant, anti-platelet effects and anti-inflammatory
effects [17]. For instance, statins inhibit a number of inflammatory
processes during brain damage and suppress the release of cyto-
kines including interleukin (IL)-1b and tumor necrosis factor-a
(TNF-a) in neurological diseases or animal disease models, such as
human multiple sclerosis [16-18], X-adrenoleukodystrophy [19],
experimental autoimmune encephalomyelitis [20], [21], Parkin-
son’s disease [22], spinal cord injury [23], brain ischemia [24],
[25], Alzheimer’s disease [26], metabolic syndrome [27], and
acute brain injury [28–30].
A recent study has compared 9 known statins by analyzing
parameters possibly related to neuroprotection. Results suggest
that simvastatin presents the best characteristics for neuroprotec-
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barrier penetration capacity and cholesterol-lowering effect on
neurons [29]. Study from the same group has also suggested that
simvastatin is the most effective statin protecting against kainate-
induced excitotoxicity and memory impairment [30], which might
be related to the role of statins in regulating NMDA receptors
[31]. In addition to anti-excitotoxic effect, simvastatin has also
shown anti-inflammation effect via reducing expression of
interleukin-1 [32–35].
Although studies of the efficacy of statins (atorvastatin and
simvastatin) in animal model of TLE have shown an anti-seizure
effect, only transient outcome (ranging from 3 days to 2 weeks after
SE) of statins treatment were evaluated [30], [35]. The long-term
effect of simvastatin treatment on seizure development has not
been studied. In this study, we evaluated the long-term effect of a
14-day administration of simvastatin on epileptic rat at 4 to 6
months after KA-induced SE.
Results
KA-lesion Induced Behavioral Deficits in Rat Model
Within 20–30 min after KA injection (i.c.v), all animals
developed status epileptic (SE) and convulsive seizures lasted at
least for 1–2 h. Seizure behavior was characterized by animal’s
rolling toward one side, rotating, and stiffing of limbs and tail.
Epileptic rats showed no movement during the interphase of
spasms. After a relatively quiescent period (ranging from 10 days
to 2 months), 75% rats developed spontaneous seizures that were
often evoked by grasping and/or arousing the rats. In the control
group, rats with saline injection (i.c.v) did not exhibit any of these
abnormal behaviors.
Simvastatin Down-Regulated the Expression of IL-1b and
TNF-a without Altering Expression of IL-6 in the Injured
Hippocampus
We first investigated the effect of simvastatin treatment on the
expression of cytokines including IL-1b, TNF-a, and IL-6 in the
KA-injured hippocampus. Three days after KA-lesion, significant
increases in expression of IL-1b (99.34611.10 vs 22.1262.30 pg/
mg at normal level), TNF-a (18.1061.69 vs 4.1260.68 pg/mg),
and IL-6 (163.11623.45 v.s. 45.1266.93 pg/mg) were observed
in hippocampus (Fig. 1). Compared to saline treatment, 3-day
administration of simvastatin significantly suppressed KA-induced
up-regulation of IL-1b (31.4767.10 pg/mg) and TNF-a (10.136
1.19 pg/mg) in hippocampus (Fig. 1A and B), while it showed no
effect on lesion-induced up-regulation of IL-6 (154.13616.97 pg/
mg) (Fig. 1C).
GFAP-positive Astrocytes Reduced after Simvastatin
Treatment
In response to brain injury, astrocytes become reactive and
express various inflammatory mediators that play important roles
in the secondary injury. KA-lesion induced reactive astrocytes are
often identified by increased immunoreactivity of glial fibrillary
acidic protein (GFAP). In the normal brain, only a few astrocytes
expressed GFAP and GFAP-positive astrocytes showed slim
morphology as well as thin and long processes (Fig. 2A1 and
A2). Two-week simvastatin treatment attenuated this lesion-
induced GFAP immunoreactivity at 4 months in the epileptic
rats. GFAP-positive astrocytes also lost fine processes (Fig. 2B1 and
B2). In contrast, 4 months after KA-lesion, saline-treated group
showed a robust increase in GFAP immunoreactivity and
hypertrophic morphology of astrocytes. (Fig. 2C1 and C2).
Quantitative data showed that the density of GFAP-positive cells
in dentate hilar (DH) area was reduced compared to saline-treated
epileptic rats (Fig. 2D). We also evaluated the reactive astrocytosis
at 5 and 6 month post KA-lesion. Our data showed that the
simvastatin-mediated suppression in reactive astrocytosis lasted
until 6 month post-lesion (Fig. 2E).
Simvastatin Administration Restrained KA-induced injury
in Hippocampal Cytoarchitecture
Hippocampal cytoarchitecture was evaluated using Nissl
staining in different groups at 4 months after the KA-lesion. In
this study, the number of neurons in the CA3 and DH region was
counted and compared among each group (Fig. 3). Out results
showed that KA-lesion induced dramatic degeneration of neurons
in CA3 and DH in ipsilateral hippocampus at 4 months. However,
the number of neurons in the simvastatin-treated group was
Figure 1. Simvastatin altered the expression level of IL-1b and TNF-a. Bar graphs showed the level of IL-1b (A), TNF-a (B), and IL-6 (C) in the
hippocampus 3 days post KA-lesion. KA-injured rats were treated with simvastatin or saline for 3 days. Data were presented as means6standard
deviation. *P,0.05 versus control group; #P,0.05 versus the saline group. IL-1b and TNF-a expression was decreased at day 3 after simvastatin
treatment compared with that in saline-treated group. However, simvastatin did not suppress the expression of IL-6 compared with the saline-treated
group.
doi:10.1371/journal.pone.0024966.g001
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time. These data suggest that simvastatin treatment can rescue the
loss of neurons in CA3 and DH region.
Simvastatin Treatment Restrains KA-lesion Induced
Mossy Fiber Sprouting (MFS)
Mossy fibers from granule cells in the DH undergo reorgani-
zation of their terminal projections in both human epilepsy and
animal models of epilepsy. In this study, KA lesion-induced
aberrant MFS was shown by Timm’s method that selectively
labeled synaptic terminals of mossy fibers due to their high zinc
content. The effect of saline and simvastatin-treatment on KA-
induced MFS was assessed at 6 months post-lesion. In the saline-
treated group, Timm’s staining showed robust MFS that extended
into the dentate supragranular layer (DSGL) (Fig. 4A1, A2). On
the contrary, in the simvastatin-treated group (Fig. 4B1, B2),
supragranular MFS was less intense and more dispersed, though it
is still more dense than that in the normal brain (Fig. 4C1, C2). We
further compared the average width and Timm’s staining density
between simvastatin- and saline-treated groups. We found that
simvastatin-treatment reduced MFS width and staining density in
all upper blade (UB), lower blade (LB) and crest area of DH. These
data suggest that simvastatin-treatment restrained KA-induced
abberant MFS.
Simvastatin Inhibits Abnormal Spike Discharges of the
Epileptic Brain as Observed by EEG Monitoring
The activity from the hippocampus was monitored with
electronic encephalography (EEG) during 4 to 6 months after
KA-lesion. Abnormal spikes in EEG showed high amplitude and
sharp peak and they were manifested by asterisks (Fig. 5A–C). The
EEG data from hippocampus of rats consisted of waves with a
frequency ranging from 0 to 75 Hz and amplitude of 500 mV.
Quantitative data showed the comparison of EEG data at 4, 5,
and 6 months after KA-lesions. Simvastatin-treated group
presented a significant lower frequency (4 months: 24.867.2/
min, 5 months: 28.164.2/min, 6 months: 31.065.1/min) of
abnormal spikes than the saline-treated group (4 months:
Figure 2. Immunostaining of GFAP for reactive astrocytes in hippocampus at 4, 5 and 6 months post-lesion. (A1–A2) In the normal
brain, GFAP staining (brown) showed slim astrocyte morphology and HE staining showed normal neuron (blue) number. Higher magnification of
insert was presented in A2. (B1–B2) Simvastatin-treated group exhibited astrocytic hypertrophy and moderate reduction in neurons. (C1–C2) Animals
with KA-lesion followed by saline administration showed pronounced up-regulation of GFAP expression. GFAP-positive astrocytes exhibited
hypertrophy and atrophied processes. The number of neuron was also severely reduced. (D–E) Quantification of GFAP-positive cells in DH area of
hippocampus. Scale bar=400 mm in C1 (applies to A1, B1, C1); scale bar=100 mm in C2 (applies to A2, B2, C2). (* P,0.05, vs. the control group;
# P,0.05, vs. the saline-treated group).
doi:10.1371/journal.pone.0024966.g002
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61.468.6/min). These results suggest that simvastatin-treatment
in injured hippocampus could reduce the abnormal discharge of
the epileptic brain.
Statin attenuates seizure behavior induced by kainic acid
In the present study, we observed seizure behavior (seizure
score) at 4-6 months after KA injection (i.c.v) (Fig. 6). The rats
were orally treated 0.5 h with simvastatin (1 mg/kg) after KA
injection (1.0 ml of KA. i.c.v). Simvastatin attenuated the seizure
score. Seizure activity was rated according to the Racine’s scale:
Stage I, facial clonus; Stage II, nodding and wet dog shaking;
Stage III, unilateral forelimb clonus with lordotic posture; Stage
IV, lateral forelimb clonus with rearing; Stage V, bilateral forelimb
clonus with rearing, jumping, and falling.
Discussion
In this study, we found that 14-day simvastatin-treatment
immediately after KA-lesion was effective in long-term inhibition
of TLE until 6 months, which might be due to the suppression of
reactive astrogliosis and neuroinflammation. Simvastatin treat-
ment also attenuated aberrant MFS from granular cells in DH,
which may lead to decreased discharges of epileptic brain. These
findings suggest that simvastatin could reduce KA-induced lesion
in hippocampus and simvastatin administration may become a
possible intervention for impeding the progression of status
epilepticus to chronic epilepsy.
Simvastatin inhibits neuroinflammation and reduces
reactive astrocytosis
Pro-inflammatory cytokines play key roles in the epileptogenic
cascade [9–13], [36–38] including seizure-related pathological
changes in hippocampus, such as neuronal death, reactive gliosis
and abberant mossy fiber sprouting. In rat model of KA-induced
epilepsy, injury in hippocampus occurs accompanied by upregula-
tion of cytokines including TNF-a and IL-1 in glial cells.
Production of cytokines further precedes neuronal degeneration
[39], [40]. Reducing TNF-a level by employing thalidomide has
showed effective antiepileptic activity [41]. IL-1b, another critical
Figure 3. Hippocampal cytoarchitecture visualized with Nissl staining. A1, A2, A3 and A4 showed hippocampal regions from rats with
intracerebroventricular saline injection. B1, B2, B3 and B4 showed regions of hippocampus from KA-injured rat followed by simvastatin treatment. C1,
C2, C3 and C4 showed hippocampal regions from KA-injured rat followed by saline-treatment. D showed quantitative data of the number of neurons
in DH and CA3. scale bar=400 mm in A1 (applies to B1, C1, A3, B3, C3); scale bar=100 mm in A2 (applies to B2, C2, A4, B4, C4 ). (* P,0.05, vs. control
group, # P,0.05, vs simvastatin-treated group).
doi:10.1371/journal.pone.0024966.g003
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seizure susceptibility in rats brain [42]. Intracerebral injection of
high dose IL-1b, which is sufficient to generate limbic seizures in
wild type mice, fails to cause seizures in transgenic mice with
deficient IL-1b receptors [43]. The effect of IL-6 in epileptic brain
is still controversial. Some studies indicate that IL-6 might be
neuroprotective through activating the synthesis of corticotrophin
and glucocorticoids, and initiating an anti-inflammatory feedback
loop [44], [45]. Therefore, manipulating level of cytokines in
inflammatory cascades could have a potential effect on KA-
induced injury.
Previous studies suggest a role of simvastatin in suppression of
cytokines by regulating nuclear factor-kB transcription pathway
[46] and decreasing isoprenylation protein involved in cellular
signaling [47] or Rac1/PI3K/PKB-dependent caspase-1 activa-
tion [48]. In this study, we observed simvastatin-induced decrease
in IL-1 b and TNF-a in injured hippocampus as early as 3 days
after KA-lesion. The reduction of IL-1 b and TNF-a in early stage
after injury attenuates secondary inflammation damage, which
may contribute to the improvement of pathological changes in
hippocampus. Our founding supports the hypothesis that
simvastatin-mediated early suppression of the inflammatory
cascade may result in a marked reduction in secondary neuronal
damage after SE.
Evidence has also shown that simvastatin-treatment increases
brain-derived neurotrophic factor (BDNF)expression in hippo-
campus after traumatic brain injury (TBI) [34]. Moreover,
supplementation of BDNF attenuates astrocytosis and IL-1b
expression after status epilepticus [49]. Therefore, the neuropro-
tective effect of simvastatin observed in this study may be also
related to increased BDNF level that prevents neurons from lesion-
induced degeneration. Thus, both anti-inflammation and neuro-
trophy effect of simvastatin may contribute to its neuroprotective
role found in our study.
Astrocytes also play a critical role in epileptogenesis [50–52],
particularly in chronic relapsing forms, which is associated with
Figure 4. Comparison of KA-lesion induced MFS using Timm’s staining in DH. The extent of aberrant MFS in saline-treated group with
severe hippocampal injury (A1and A2), simvastatin-treated group with moderate hippocampal injury (B1 and B2) and in comparison with rats with
intracerebroventricular saline injection (C1 and C2), visualized by Timm’s histochemical staining. Quantitative data for width and density of sprouting
into DSGL were presented in (D and E). GCL, granule cell layer, UB, upper blade; LB, lower blade. Scale bars=500 mm in A1 and 200 mm in A2.
(*P,0.05, vs. the simvastatin-treated group).
doi:10.1371/journal.pone.0024966.g004
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astrocytosis is also a source of cytokines including IL-1b, TNF-a,
and IL-6 [53]. Reactive astrocytosis may exacerbate inflammation
by inducing the migration of other leukocytes into the injured site,
interrupting blood-brain-barrier function [54], [55], and produc-
ing reactive oxygen species[56], [57] and cytotoxic edema [58].
Therefore, we also investigated the effect of simvastatin-treatment
on the extent of reactive astrocytosis after KA-lesion. Our result
showed that simvastatin-treatment reduced GFAP-positive astro-
cytes in both DH and CA3 area in the hippocampus where neuron
loss mainly occurred. This simvastatin-mediated suppression of
astrocytosis may contribute to inhibition of neuroinflammation
and neuronal loss, thus exert a neuroprotective role in KA-induced
injury.
Simvastatin attenuates aberrant MFS into the DSGL
In both human and animal models of epilepsy, due to the
degeneration of pyramidal neurons in CA3 and interneurons in
DH, axons of the granular cells (mossy fiber) lose their normal
connecting targets and sprout abnormally, which is called aberrant
MFS. The extent of MFS is influenced by the degree of neuron
loss in CA3 and DH. [59–61]. This is supported by observation
that intense MFS occurred associated with extensive loss of CA3
pyramidal neurons and hilar neurons in not only animal models of
TLE but also TLE patients. [61], [62–64]. Therefore, decreased
neuronal death after simvastatin-treatment in injured hippocam-
pus may contribute to reducing MFS.
Aberrant sprouting of mossy fiber into DSGL in KA-injured
hippocampus is known to contribute to spontaneous seizures [62–
65]. The extent of MFS has been correlated with increased seizure
susceptibility of spontaneous seizures [64], [66], [67]. Therefore,
we speculate that a lasting suppression of aberrant MFS is likely to
reduce the recurrent excitation and seizure susceptibility. In this
study, we showed that KA-injured animals with 2-week admin-
istration of simvastatin presented a significant decrease in the
frequency of discharge in 4–6 month after KA-lesions, which was
concurrent with restrained MFS in DG. This observation suggests
that simvastatin-treatment could reduce the abnormal discharge of
the epileptic brain possibly through restraining the excitation
connection derived from aberrant MFS. In addition to MFS, high
frequency of spontaneous recurrent motor seizures (SRMS) is
also associated with other features of chronic epilepsy, such as
extensive loss of inhibitory interneurons in hilar area [68], [69]
and changes in neurotransmitters expression by granule cells [70].
Figure 5 Simvastatin-treatment decreased the frequency of abnormal spikes of epileptic brain. Representative EEG recordings from
saline-treated group and simvastatin-treated group at 4 months (A), 5 months (B) and 6 months (C). Quantitative data was presented in (D). *P,0.05,
vs. the saline-treated group.
doi:10.1371/journal.pone.0024966.g005
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tory interneurons and neurotransmitter expression after simvasta-
tin treatments.
Possible mechanism underlying anti-excitotoxic effect of
simvastatin
The possible mechanisms underlying the beneficial effect of
statins on neurodegenerative and cardiovascular diseases have
been extensively investigated and discussed in previous literature.
While the study of the effect of statins in epileptic conditions has
been limited, previous research has shown the evidence supporting
the anti-excitotoxic effect of statins [17], which might explain the
beneficial effect of simvastin after KA-induced injury. For instant,
in vitro study has shown that statins, especially rosuvastatin and
simvastatin, protect cultured neurons from NDMA-induced
excitotoxic death [31].
Atorvastatin has also been shown to protect primary cortical
neurons from glutamate-induced excitotoxicity possibly by atten-
uating glutamate-induced intracellular calcium signaling that
modulating NMDA receptor function [71]. Anti-excitotoxic and
anti-seizure effects of statins have been further studied in KA
model of TLE. Pre-treatment with atorvastatin efficiently reduced
KA-induced seizure activities and neuronal loss [35]. Moreover, a
very recent in vivo study, which compared 5 commercially
available statins in KA model of TLE, suggests that simvastatin is
the most effective statin in attenuating KA-induced excitotoxicity
and improving memory [30]. Our results in the present study
further support the anti-excitotoxicity effect of statins in epileptic
conditions and this protective effect could last until 6 months after
KA-induced SE. Considering previous studies together with our
results, we suggest that the roles of statins in regulating glutamate
receptor and inhibiting injury-induced inflammatory response may
contribut to the beneficial effect in the epileptic conditions.
Simvastatin shows a long-term neuroprotective effect on
epileptic brain
Previous studies have investigated effects of two statins, atoro-
vastatin [35], [46], [72] and lovastatin [73], [74], on neuronal
protection during epileptogenesis and attenuating seizure behavior
in various animal models, including pentylentetrazole-kindled rats,
quinolinic acid-induced seizure, pilocarpine-induced status epilep-
tic and kainic-acid induced seizure. A very recent study has
compared 9 statins by analyzing several parameters that could be
related to neuroprotection and suggests that simvastatin presents
the best characteristics for preventing neurodegenerative condi-
tions, due to its high BBB penetration capacity and cholesterol
lowering effect on neurons [29]. Moreover, study performed by
the same group also shows that simvastatin is the most efficient
statin in protecting against KA-induced excitotoxicity and
memory deficits [30]. However, all animal studies above have
mainly focused on the transient effect of the statin administration,
ranging from 3 days to 2 weeks after SE. In the present study, we
evaluated the long-term neuroprotection of simvastatin at 4, 5 and
6 months after KA-induced SE and our data showed a consistent
result as transient outcome, suggesting that a 14-day administra-
tion of simvastatin has a beneficial effect that can last for 6 months.
Our data also support previous studies of transient outcome of
statins administration. This long-term effect of simvastamin
suggests that it may have therapeutic potential in the treatment
of neurodegenerative disease involving excitotoxicity.
Conclusion
Our data showed that 2-week administration of simvastatin
immediately after KA-induced seizure lead to reduced astrocytosis,
attenuated neuronal loss, decreased abnormal MFS and reduced
seizure activity in the brain at 4 to 6 month after KA lesion,
suggesting a long-term protective role of simvastatin in the
epileptic brain. This study supports the possibility of using
simvastatin administration as a neuroprotective intervention for
retarding progression of the epileptogenesis and a therapeutic
strategy for epilepsy.
Materials and Methods
Experimental Groups
Adult male Wister rats (200–250 g) were used in our experiment
and all animals were maintained under 12 h light/dark-cycle with
free access to food and water in a temperature-controlled room.
All animal procedures were in accordance to guidelines of Ethics
Committee of the First Clinical College of Harbin Medical
University (201001). Rats were divided into 3 groups: 1) SE were
induced in rats with KA injection followed by oral administration
of saline starting at 0.5 h after SE once a day for 14 consecutive
days; 2) Rats were subjected to KA-lesion followed by oral
administration of simvastatin (1 mg/kg/day) starting at 0.5 h after
SE for 14 consecutive days. The dose was selected according to
our previous study [75]; 3) Rats were subjected to intracerebro-
ventricular saline injection as a control. Rats with KA-lesion were
sacrificed at 3 days, 4 and 6 months after simvastatin- or saline-
administration. Rat cerebral hemispheres were homogenized for
enzyme-linked immunosorbent assay (ELISA) at 3 day after KA-
lesion.
Kainic acid lesion
Rats were anesthetized with chloral hydrate (40 mg/kg body
weight, i.p.), then immobilized in a stereotaxic apparatus (WPI
Stoelting, USA) with a plane of incision bar set at 3.360.33 mm
below the interaural line. After making a midline incision, the skull
was exposed and one burr hole was drilled according to the
coordinates: 3.7 mm posterior to the bregma, 4.1 mm lateral to
the midline, and 3.5 mm under the dura. Each rat was injected
with 1.0 ml of KA (0.5 mg in 1.0 ml Saline) in the right lateral
Figure 6. Simvastatin attenuated KA-induced seizure behavior
in rats. The rats were orally treated with simvastatin (1 mg/kg) for
0.5 h after KA injection (1.0 ml of KA. i.c.v). The seizure behavior test
(seizure score) was performed during 4–6 months after KA injection
(1.0 ml of KA. i.c.v). Simvastatin attenuated the seizure score. Data were
presented as means6standard deviation. *P,0.05 versus the saline
group.
doi:10.1371/journal.pone.0024966.g006
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further used for experiments.
Tissue processing
Rats were deeply anesthetized with chloral hydrate (40 mg/kg
body weight, i.p.). For Timm’s staining rats were perfused with
100–150 ml sodium sulfide followed by post-fixation in 4%
paraformaldehyde (PFA) for 10 h and then brains were transferred
into cryo-protection solution (30% sucrose). For Nissl staining, HE
staining and immunohistochemistry rats were perfused with
phosphate-buffered saline (PBS) followed by post-fixation in 4%
PFA for 72 h and brains were embedded with paraffin.
Nissl staining
The surviving neurons in the hippocampus were visualized
by Nissl staining [76], [77]. The mounted sections were
rehydrated in distilled water, and submerged in 0.5% cresyl violet
solution for 10 min until the desired depth of staining was
achieved.
GFAP staining
After deparaffinization, brain sections were incubated in
2% bovine serum albumin (BSA) in PBS at room temperature
for 30 min, and subsequently incubated with mouse anti-GFAP
antibody (1:160 diluted in PBS; sigma) at 4uC overnight.
After washing in PBS, sections were incubated in peroxidase
blocking solution for 10 min at room temperature. Sections were
then sequentially incubated with biotin-conjugated anti-mouse
immunoglobulin G (1:100 dilution; sigma) for 10 minutes,
streptavidin-HRP in PBS for 30 min, and DAB solution for 1-
3 min. Sections were washed in PBS between each step and all
these incubation were performed at room temperature. Sections
were then counterstained with HE, rinsed in distilled water,
dehydrated through 95% ethanol for 2 min, 100% ethanol for
263 min and then cleared in xylene for 265 min for coverslip
mounting.
Timm’s staining
Serial coronal sections (8 mm) were collected with a cryocut
(Leica VT 1000S). Every fifth section was collected on slides and
dried at room temperature overnight. For the visualization of
MFS, sections were developed using the following solution: 120 ml
of 50% gum arabic, 10 ml of 47% sodium citrate buffer, 10 ml of
51% citrate buffer, 60 ml of 5.78% hydroquinone and 212.25 mg
silver nitrate. The physical development was performed in the
dark at room temperature for 120 min. The sections were rinsed
in tap water, then dehydrated, cleared, and coverslipped in
Entellan (107961.0100; Merck). Evaluation of Timm’s staining
was performed according to the method introduced by Shetty and
Turner [78]. Both the average width and the density of the MFS in
the DSGL were measured in all regions of the DG (The upper and
lower dentate blades and the crest). The scores were recorded for
the DG in coronal sections from the ipsilateral dorsal hippocam-
pus by an observer who was blind to the groups.
ELISA
ELISA kit (Promega Corp. Madison, WI) was used to deter-
mine the protein concentration and the procedure was performed
according to the instructions provided by the company. Lysis
buffer was added to the tissue sample and the protein was obtained
by centrifuging the solution at 14000 rpm for 12 min at 4uC.
The expression of IL-1b, TNF-a, and IL-6 at 3 days after SE
were measured using equal amounts of lysate from hippocampus
tissues.
Electrode implantation
At 4 months after KA-lesion, the rats were again anesthetized
with chloral hydrate (40 mg/kg body weight, i.p.) and fixed into
stereotaxic apparatus (WPI, Stoelting, USA). A bipolar electrode,
consisting of two twisted strands of stainless steel wire, was
stereotactically implanted into the right hippocampus using
the following coordinates: AP=25.6 mm, L=4.5 mm and
V=2.6 mm. A single stainless steel wire was inserted into the
left frontal cortex acting as earth electrode. The electrodes were
attached to male connector pins, which were inserted into a
connector strip. Stainless steel screws were threaded into the right
and left parietal cranium to help fix the electrode. The electrode
assembly was then fixed to the skull with acrylic resin before the
scalp was sutured.
EEG examination and analysis
Starting at 3 days after electrode implantation, all rats
underwent 3 EEG examination sessions per week with 4 h of
continuous monitoring per session. Recordings were performed in
the afternoon to minimize potential circadian variations, following
the habituation of the rats to the test cage. For spike evaluation,
the EEG from the hippocampus of rats consisted of waves with a
frequency ranging from 0 to 75 Hz. The data were collected to
evaluate average spikes at 4 to 6 months post KA-lesion.
Image analysis
Imaging analysis was performed according to method describe
previously [79]. A series of every fifth section of each animal were
used for analysis. For neuron counting, in each section, the
contour of CA3 pyramidal cell layers, and DH was first delineated
with the tracing function of StereoInvestigator(Microbrightfield
Inc.,Williston, VT). After this, the optical fractionator component
was activated, and the number and location of the counting frames
and the counting depth for that section were determined by
entering parameters such as the grid size (2006200 mm for CA3
cell layers, and 60660 mm for the DG), the thickness of the guard
zone (4 mm), and the optical dissector height (8 mm). A computer-
driven motorized stage hen allowed the section to be analyzed at
each of the counting frame locations. All nissl-positive cells that
were present in the 8 mm section depths were counted in each of
the chosen serial sections. The StereoInvestigator program
calculated, based on the above-described parameters and cell
counts, the total number nissl-positive cells in each of the above-
mentioned hippocampal regions. For GFAP counting, similar
method was used and the total number of GFAP-positive
astrocytes was quantified in DH and CA3 area.
Statistical analysis
All data were presented as mean6SEM. One-way analysis of
variance (ANOVA) with Newman-Keuls multiple comparisons test
was employed for comparison. The operations were performed
using StatView software (version5.0, SASinstitute Inc., Cary, NC,
USA). Statistical significance was set at P,0.05.
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